文献速递心外重症与机械循环支持

左心室辅助装置植入术后肝功能不全对生存的影响

Impact of Postoperative Liver Dysfunction on Survival After Left Ventricular Assist Device Implantation.
PubMed 文献 · Ann Thorac Surg · 2017-07-29

该单中心回顾性研究分析了2005年1月至2014年6月明尼苏达大学284例植入HeartMate II左心室辅助装置的患者,排除14例术前肝功能不全后纳入270例。术后肝功能不全(PLD)定义为住院期间转氨酶升高和/或胆红素升高,发生率为47.8%。合并转氨酶及胆红素升高者30天、90天和1年死亡率显著更高,死亡风险显著高于无PLD者(风险比4.6,95%CI 2.1-10.1,P<0.001)。

要点

  • LVAD术后单纯胆红素升高常见,未增加早中期死亡风险。
  • 术后转氨酶与胆红素同时升高者死亡风险显著增加(HR 4.6)。
  • 此类患者输血需求、肾脏替代治疗、延长通气和升压药使用率更高。

核心结论

  • LVAD术后单纯高胆红素血症常见,但与早中期死亡率增加无关。
  • 术后转氨酶升高合并高胆红素血症与早中期并发症和死亡率显著增加相关。
  • 需进一步研究LVAD术后肝功能不全的发病机制。

研究设计与样本

  • 单中心回顾性队列研究,分析2005年1月至2014年6月明尼苏达大学284例植入HeartMate II LVAD的患者。
  • 排除14例术前肝功能不全者,最终纳入270例。
  • PLD定义为LVAD植入住院期间出现高转氨酶血症和/或高胆红素血症。

主要发现

  • 最终队列270例中,129例(47.8%)发生PLD:单纯高转氨酶血症16例(12.4%),单纯高胆红素血症76例(58.9%),两者合并37例(28.7%)。
  • 合并高转氨酶和高胆红素组(III组)30天、90天和1年死亡率显著更高。
  • III组输血需求、肾脏替代治疗、延长通气和升压药使用率显著更高。
  • III组死亡风险显著高于无PLD者(风险比4.6,95%CI 2.1-10.1,P<0.001)。

临床怎么用

  • LVAD术后应监测转氨酶和胆红素,单纯胆红素升高可能无需过度担忧。
  • 若转氨酶与胆红素同时升高,提示早中期死亡和并发症风险显著增加,需加强管理。

局限性

  • 单中心回顾性研究,仅纳入HeartMate II LVAD,结果外推需谨慎。
  • PLD定义基于住院期间实验室指标,未涉及具体阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver dysfunction in left ventricular assist device (LVAD) recipients is common both before and after implantation. Postoperative liver dysfunction (PLD) develops in some LVAD recipients without preoperative liver dysfunction. The aim of this study was to assess clinical outcomes in such patients. METHODS: Records of all patients undergoing implantation of a HeartMate II (HM II, St. Jude Medical, Inc, Minneapolis, MN) LVAD at a single center at the University of Minnesota from January 2005 through June 2014 were analyzed. PLD was defined by hypertransaminasemia or hyperbilirubinemia, or both, during the hospitalization for LVAD implantation. RESULTS: During the study period, 284 patients underwent HM II implantation. Excluded from analysis were 14 recipients with preoperative liver dysfunction. In the final cohort (n = 270), there were no major difference in preoperative characteristics among those patients with versus without PLD. PLD developed in 129 (47.8%) recipients: 16 (12.4%) had isolated hypertransaminasemia (group I), 76 (58.9%) had isolated hyperbilirubinemia (group II), and 37 (28.7%) had combined hypertransaminasemia and hyperbilirubinemia (group III). Group III LVAD recipients had significantly greater rates of 30-day, 90-day, and 1-year mortality, along with significantly higher transfusion requirements and higher rates of renal replacement therapy, prolonged ventilation, and vasopressor use. Moreover, their mortality risk was significantly higher than that of PLD-free LVAD recipients (hazard ratio, 4.6; 95% confidence interval, 2.1 to 10.1; p < 0.001). CONCLUSIONS: Isolated hyperbilirubinemia is common after LVAD implantation. In this study, it was not associated with an increase in early or midterm postoperative mortality. However, postoperative combined transaminasemia and hyperbilirubinemia was associated with a significant increase in early and midterm morbidity and mortality. Further research into the pathogenesis of post-LVAD PLD is necessary.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Majumder K, Spratt JR, Holley CT, et al. Impact of Postoperative Liver Dysfunction on Survival After Left Ventricular Assist Device Implantation. Ann Thorac Surg. 2017. PMID: 28760474. doi:10.1016/j.athoracsur.2017.04.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。